Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Details of immune-related adverse events (AEs) in the study cohort

From: Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas

Immune-related AEs Any grade
(# of patients)
Any grade
(% of patients)
Grade 3 or 4
(# of patients)
Grade 3 or 4
(% of patients)
All types 8a 23.5%a 3 8.8%
Dermatitis – Rash 1 2.9% 0 0
Colitis 2 5.9% 0 0
Thyroiditis 3 8.8% 0 0
Pneumonitis 3 8.8% 2 5.9%
Thrombocytopenia 1 2.9% 0 0
Others
 Autonomic dysregulation 1 2.9% 1 2.9%
 Renal graft rejection 1 2.9% N/A N/A
  1. aSome patients developed more than one type of immune-related AEs